Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TransCode Therapeutics ( (RNAZ) ) has provided an update.
On February 5, 2026, TransCode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, announced that it had submitted an Investigational New Drug application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate TTX-MC138 in colorectal cancer. The trial, to be run within Quantum Leap’s PRE-I-SPY platform and representing that program’s first expansion into colorectal cancer, is expected to enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy but show positive circulating tumor DNA markers, a prognostic indicator of minimal residual disease and recurrence risk. Led by Dr. Paula Pohlmann of MD Anderson Cancer Center and conducted across multiple PRE-I-SPY network sites with support from the Colorectal Cancer Alliance, the study is intended to assess the biological and clinical activity of TTX-MC138 in the minimal residual disease setting, potentially strengthening TransCode’s clinical development program and its positioning in innovative oncology trial platforms if successful.
The most recent analyst rating on (RNAZ) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis, and the company is developing a broader portfolio of first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells.
Average Trading Volume: 58,599
Technical Sentiment Signal: Sell
Current Market Cap: $7.87M
For an in-depth examination of RNAZ stock, go to TipRanks’ Overview page.